Jardiance (empagliflozin)

news

Jardiance^® displays 21 percent risk reduction in heart failure patients

31 August 2021 | By Anna Begley (European Pharmaceutical Review)

Jardiance displayed a 21 percent risk reduction in adults with heart failure with preserved ejection fraction in Phase III study.

news

FDA approves Jardiance^® for heart failure with reduced ejection fraction

19 August 2021 | By Anna Begley (European Pharmaceutical Review)

The FDA have approved Lilly’s Jardiance (empagliflozin) to treat adults living with heart failure with reduced ejection fraction.

news

Fast Track designation granted to chronic kidney disease treatment

16 March 2020 | By Rachael Harper (European Pharmaceutical Review)

The US FDA has granted Fast Track designation to Jardiance® for the treatment of chronic kidney disease.

news

British Columbia first province to switch patients to biosimilars

30 May 2019 | By European Pharmaceutical Review

British Columbia has said it will switch as many as 20,400 patients from three branded biologic drugs to cheap biosimilars.

news

Boehringer Ingelheim receives two FDA approvals

4 August 2014 | By Boehringer Ingelheim

Boehringer Ingelheim today announced the U.S. Food and Drug Administration (FDA) approved two different products at the end of last week.